Effect of cilnidipine on normal to marginally elevated urine albumin-creatinine ratio in asymptomatic non-diabetic hypertensive patients: An exponential decay curve analysis

Clinical Drug Investigation

Volumn 30, Issue 10, 2010, Pages 699-706

  Nakatsu, Takaaki ^a,b   Toyonaga, Shinji ^a   Mashima, Keiichi ^a   Yuki, Yoko ^a   Nishitani, Aya ^a   Ogawa, Hiroko ^b   Miyoshi, Toru ^b   Hirohata, Satoshi ^b   Izumi, Reishi ^a   Kusachi, Shozo ^b  

^a Kagawaken Saiseikai Hospital   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

calcium channel antagonists; cilnidipine; hypertension; proteinuria; therapeutic use; treatment; treatment.; type 2 diabetes mellitus

Indexed keywords

ALBUMIN; CILNIDIPINE; CREATININE; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DRUG EFFECT; ESSENTIAL HYPERTENSION; HUMAN; MICROALBUMINURIA; MORNING DOSAGE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ALBUMINURIA; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; HYPERTENSION; PATHOPHYSIOLOGY; PHOTOMETRY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; URINE;

ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; CREATININE; DIHYDROPYRIDINES; HUMANS; HYPERTENSION; MODELS, STATISTICAL; NEPHELOMETRY AND TURBIDIMETRY; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955570272     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11538510-000000000-00000     Document Type: Article

References (40)

1. Tominaga M, Ohya Y, Tsukashima A, et al. Ambulatory blood pressure monitoring in patients with essential hypertension treated with a new calcium antagonist, cilnidipine. Cardiovasc Drugs Ther 1997 Mar; 11 (1): 43-48
2. Uneyama H, Takahara A, Wakamori M, et al. Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (review). Int J Mol Med 1999 May; 3 (5): 455-466
3. Takahara A, Fujita S, Moki K, et al. Neuronal Ca2+ channel blocking action of an antihypertensive drug, cilnidi- pine, in IMR-32 human neuroblastoma cells. Hypertens Res 2003 Sep; 26 (9): 743-747
4. Zhou X, Ono H, Ono Y, et al. N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe ne- phrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens 2002 May; 20 (5): 993-1000
5. Rose GW, Kanno Y, Ikebukuro H, et al. Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephro- sclerosis. Hypertens Res 2001 Jul; 24 (4): 377-383
6. Konda T, Enomoto A, Matsushita J, et al. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005; 101 (1): p1-13
7. Konda T, Enomoto A, Takahara A, et al. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol Pharm Bull 2006 May; 29 (5): 933-937
8. Haffner SM, Stern MP, Gruber MK, et al. Microalbumin-uria: potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis 1990 Sep- Oct; 10 (5): 727-731
9. Murussi M, Campagnolo N, Beck MO, et al. High-normal levels of albuminuria predict the development of micro- and macroalbuminuria and increased mortality in Brazilian type 2 diabetic patients: an 8-year follow-up study. Diabet Med 2007 Oct; 24(10): 1136-1142
10. Pedrinelli R, Dell'Omo G, Giampietro O, et al. Dissociation between albuminuria and insulinaemia in hypertensive and atherosclerotic men. J Hum Hypertens 1999 Feb; 13 (2): 129-134
11. Cirillo M, Stellato D, Laurenzi M, et al. Pulse pressure and isolated systolic hypertension: association with microal- buminuria. The GUBBIO Study Collaborative Research Group. Kidney Int 2000 Sep; 58 (3): 1211-1218
12. Dell'Omo G, Penno G, Giorgi D, et al. Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis 2002 Jul; 40 (1): 1-8
13. Fujiwara T, Matsubara M, Ohkubo T, et al. Study design of HOMED-BP: hypertension objective treatment based on measurement by electrical devices of blood pressure. Clin Exp Hypertens 2003 Apr; 25 (3): 143-144
14. Mashima K, Nakatsu T, Murakami T, et al. Exponential- exponential cosine fitting of blood pressure decay induced by a long-acting calcium blocker, amlodipine, using home blood pressure measurement. Clin Exp Hypertens 2003 Apr; 25 (3): 145-154
15. Chalmers J, MacMahon S, Mancia G, et al. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 1999 Jul-Aug; 21 (5-6): 1009-1060
16. Kuzuya T, Nakagawa S, Satoh J, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002 Jan; 55 (1): 65-85
17. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res 1997; 35: 2-3
18. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999 May; 33 (5): 1004-1010
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 Jun; 18 (6): 499-502
20. Schectman G, Patsches M, Sasse EA. Variability in cholesterol measurements: comparison of calculated and direct LDL cholesterol determinations. Clin Chem 1996 May; 42 (5): 732-737
21. Kawano K. Quality control, quality assessment of laboratory tests, HbA1c. Southeast Asian J Trop Med Public Health 1999; 30 SUPPL. 3: 117-121
22. Khuu HM, Robinson CA, Goolsby K, et al. Evaluation of a fully automated high-performance liquid chromatography assay for hemoglobin A1c. Arch Pathol Lab Med 1999 Sep; 123 (9): 763-767
23. Watts GF, Bennett JE, Rowe DJ, et al. Assessment of im-munochemical methods for determining low concentrations of albumin in urine. Clin Chem 1986 Aug; 32 (8): 1544-1548
24. Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to protei- nuria in hypertensive patients with renal diseases. Hypertens Res 2004 Jun; 27 (6): 379-385
25. Tsuchihashi T, Ueno M, Tominaga M, et al. Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine. Clin Exp Hypertens 2005 Nov; 27 (8): 583-591
26. Ritz E. Heart and kidney: fatal twins? Am J Med 2006 May; 119 (5 SUPPL. 1): S31-9
27. Rachmani R, Levi Z, Lidar M, et al. Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. Diabetes Res Clin Pract 2000 Aug; 49 (2-3): 187-194
28. Cubeddu LX, Hoffmann IS, Aponte LM, et al. Role of salt sensitivity, blood pressure, and hyperinsulinemia in determining high upper normal levels of urinary albumin excretion in a healthy adult population. Am J Hypertens 2003 May; 16(5Pt 1): 343-349
29. Fujimoto S, Satoh M, Nagasu H, et al. Azelnidipine exerts renoprotective effects by improvement of renal micro- circulation in angiotensin II infusion rats. Nephrol Dial Transplant 2009 Dec; 24 (12): 3651-3658
30. Fan YY, Kohno M, Nakano D, et al. Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats. J Hypertens 2009 Sep; 27 (9): 1855-1862
31. Shokoji T, Fujisawa Y, Kiyomoto H, et al. Effects of a new calcium channel blocker, azelnidipine, on systemic hemo- dynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. Hypertens Res 2005 Dec; 28 (12): 1017-1023
32. Fujita T, Ando K, Nishimura H, et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin- angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007 Dec; 72 (12): 1543-1549
33. Ohishi M, Takagi T, Ito N, et al. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study. Hypertens Res 2007 Sep; 30 (9): 797-806
34. Abe M, Okada K, Maruyama T, et al. Comparison of the antiproteinuric effects of the calcium channel blockers be- nidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertens Res 2009 Apr; 32 (4): 270-275
35. Wright Jr JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002 Nov 20; 288 (19): 2421-2431
36. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 Sep 20; 345 (12): 851-860
37. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005 Mar 12-18; 365 (9463): 939-946
38. Koike H, Kimura T, Kawasaki T, et al. Azelnidipine, a long- acting calcium channel blocker with slow onset and high vascular affinity. Ann Rep Sankyo Res Lab 2002; 54: 1-64
39. Isaka T, Ikeda K, Takada Y, et al. Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocor-tical cell line NCI-H295R. Eur J Pharmacol 2009 Mar 1; 605 (1-3): 49-52
40. Hayashi K, Wakino S, Homma K, et al. Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J Pharmacol Sci 2005 Nov; 99 (3): 221-227